Artificial Intelligence (AI) In Precision Therapies Market Size, Share, Opportunities, And Trends By Therapy Type (Personalized Medicine, Targeted Therapies, Gene Therapies, Cell Therapies, Immunotherapies, Others), By Application (Oncology, Neurology, Cardiology, Infectious Diseases, Rare Diseases, Autoimmune Diseases, Others), By End-User Industry (Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Research Institutes And Academic Centers, Others), And By Geography - Forecasts From 2024 To 2029

Artificial intelligence (AI) in the precision therapies market is expected to grow at a CAGR of 27.56%, reaching a market size of US$7.506 billion in 2029 and US$2.223 billion in 2024.

AI in the precision therapies market is a unique and disruptive method that is revolutionizing personalized medicine and patient care. Custom-made medication aims to tailor medical treatments to individual patients’ genetics, way of life, and disease characteristics to achieve the best results with the least side complications. Within this field, the application of AI technology has become much faster in exploring potential biomarkers, targets for drug action, options for treatment, and inefficient data management and stratification of patients. Suitable AI techniques can handle large volumes of patient records, genetic information, and outcomes from clinical trials, thus assisting healthcare providers in administering their patients with targeted medications and therapies.

The market of AI in precision therapies is considerably promising in that it could reshape the healthcare sector into more effective and patient-oriented therapies.

What are the artificial intelligence (AI) in the precision therapies market growth drivers?

• Rising trends in personalized and precision medicine are increasing the Artificial Intelligence (AI) in precision therapies market growth.

AI technologies employed in precision therapies are rising due to changes in personalized and precision medicine. These changes stress the importance of customizing medical interventions to different patients who have varying genetic makeups, lifestyles, and disease characteristics. New technologies and molecular biology have made identifying various biomarkers and therapeutic targets possible, making treatment more accurate and specific. AI is pivotal in predicting treatment responses and disease outcomes through extensive datasets such as genomes, clinical data, and real-time patient information. The growing emphasis on the effectiveness of personalized or precision medicine in promoting positive patient outcomes has led to increased uptake of AI-based systems in precision therapeutics.

• Increasing the availability of big data in healthcare enhances AI in precision therapies market growth.

The growing availability of healthcare big data is a major driver of AI in precision therapies market growth. Electronic health records, genetic sequences, medical imaging, and patient-generated data are all creating massive amounts of data in healthcare systems. This data offers important insights into illness patterns, treatment responses, and patient outcomes. AI systems can analyze this data to find patterns, develop novel biomarkers, and optimize precision medicines. The availability of healthcare big data allows for more accurate predictive modeling and personalized therapy suggestions, which improves precision medicine techniques. As data volumes increase, AI's role in capturing and understanding healthcare big data becomes increasingly important in creating precision medicines.

• Drug discovery and development propels AI in the precision therapies market growth.

Drug research and development enhancements are a significant driver of AI in the precision therapies industry. AI tools are speeding up target selection, lead optimization, and candidate screening in the traditional drug development process. To identify possible drug candidates, AI systems are capable of searching and evaluating large volumes of biomedical information, chemical structures, and clinical trials within a relatively shorter time frame and with more accuracy than human effort. AI spends less time in the medication discovery process and reduces the expenses associated with it because it can anticipate the interaction of drugs with their targets and assess the safety profile of the medicines under development. Implementing AI in the drug discovery process may enhance the accuracy of medications for many diseases and present new drug treatment possibilities.

• AI's contribution to clinical trial optimization boosts AI in precision therapies market size.

Artificial intelligence's importance in optimizing clinical trials is another important area within the market of AI solutions for precision medicine. AI helps with patient recruitment, protocol design, and data management in clinical studies. Using AI algorithms, patient groups satisfying particular characteristics can be identified more quickly to facilitate recruitment and enhance the efficiency of the overall conduct of the trial. Using big data, AI examines how patients will respond to certain treatments, and this helps create better protocols and target patients. Monitoring safety and treatment effectiveness with AI in trial participants’ data ensures that issues are fixed in real time and enhances clinical trials' success. Using AI in clinical trial optimization translates to faster drug development timelines, reduced trial costs, and growth in targeted therapies.

Artificial Intelligence (AI) in Precision Therapies Market Restraints:

• Rising security concerns are anticipated to impede market growth

Issues related to safeguarding patient data can affect the competitive advantage of a business. Since increasingly sensitive patient information like Social Security numbers, insurance ID numbers, addresses, and medical data is being used in AI systems, it is important to protect patient data. The increased adoption of precision medicine strategies is against sustained growth because threats are lurking in unauthorized access, leakage of data, and even abuse of such data. A restrictive legal regime further hinders the implementation of AI-based solutions in data privacy and data security laws such as HIPAA in the United States.

What are the key geographical trends shaping the artificial intelligence (AI) in the precision therapies market?

• North America is witnessing exponential growth during the forecast period

The US has led the research, development, and use of AI technology in precision medicine and therapeutics. It is not surprising that North America leads due to its well-established healthcare facilities, high-level AI funding, and large-scale pharmaceutical and biotech companies. In addition, the region's general trend towards personalized medicine and precision healthcare has created a market for AI-infused solutions that enhance treatment and patient outcomes. Advances in AI technologies will ensure that North America remains the largest shareholder in AI in the precision therapies market.

Recent developments in artificial intelligence (AI) in the precision therapies market

• In July 2024, a team of engineers and biomedical researchers from the University of California San Diego made significant advances in creating a new generation of AI tools that enable the fast and inexpensive identification of clinically relevant genomic changes directly on tumor biopsy slides. A new AI protocol called DeepHRD for routine biopsy examination was recently published in the Journal of Clinical Oncology.
• In March 2023, Google Cloud launched new AI-based software solutions for life sciences aimed at accelerating drug development and providing solutions concerning precision medicine to pharma, biotech companies, and other organizations. The target & lead identification suite allows research teams to better characterize the role of amino acids in protein structures. This move bolstered its service offering and assisted in cementing its leadership in this competitive industry.

Artificial Intelligence (AI) In Precision Therapies Market Scope:

Report Metric	Details
AI in Precision Therapies Market Size in 2024	US$2.223 billion
AI in Precision Therapies Market Size in 2029	US$7.506 billion
Growth Rate	CAGR of 27.56%
Study Period	2019 to 2029
Historical Data	2019 to 2022
Base Year	2024
Forecast Period	2024 – 2029
Forecast Unit (Value)	USD Billion
Segmentation	Therapy Type Application End-User Industry Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in AI in Precision Therapies Market	Tempus Labs, Inc. Nvidia Corporation Deep Genomics, Inc. Microsoft Corporation Owkin, Inc.
Customization Scope	Free report customization with purchase

 

The Artificial Intelligence (AI) in precision therapies market is segmented and analyzed as follows:

• By Therapy Type
  • Personalized Medicine
  • Targeted Therapies
  • Gene Therapies
  • Cell Therapies
  • Immunotherapies
  • Others
• By Application
  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Rare Diseases
  • Autoimmune Diseases
  • Others
• By End-User Industry
  • Hospitals And Clinics
  • Pharmaceutical And Biotechnology Companies
  • Research Institutes And Academic Centers
  • Others    
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain   
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. ARTIFICIAL INTELLIGENCE (AI) IN PRECISION THERAPIES MARKET BY THERAPY TYPE

5.1. Introduction

5.2. Personalized Medicine

5.3. Targeted Therapies

5.4. Gene Therapies

5.5. Cell Therapies

5.6. Immunotherapies

5.7. Others

6. ARTIFICIAL INTELLIGENCE (AI) IN PRECISION THERAPIES MARKET BY APPLICATION

6.1. Introduction

6.2. Oncology

6.3. Neurology

6.4. Cardiology

6.5. Infectious Diseases

6.6. Rare Diseases

6.7. Autoimmune Diseases

6.8. Others

7. ARTIFICIAL INTELLIGENCE (AI) IN PRECISION THERAPIES MARKET BY END-USER INDUSTRY

7.1. Introduction

7.2. Hospitals And Clinics

7.3. Pharmaceutical And Biotechnology Companies

7.4. Research Institutes And Academic Centers

7.5. Others

8. ARTIFICIAL INTELLIGENCE (AI) IN PRECISION THERAPIES MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Therapy Type

8.2.2. By Application

8.2.3. BY End-User Industry

8.2.4. By Country

8.2.4.1. United States

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Therapy Type

8.3.2. By Application

8.3.3. BY End-User Industry

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Therapy Type

8.4.2. By Application

8.4.3. BY End-User Industry

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Italy

8.4.4.5. Spain

8.4.4.6. Others

8.5. Middle East and Africa

8.5.1. By Therapy Type

8.5.2. By Application

8.5.3. BY End-User Industry

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Therapy Type

8.6.2. By Application

8.6.3. BY End-User Industry

8.6.4. By Country

8.6.4.1. Japan

8.6.4.2. China

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Thailand

8.6.4.7. Indonesia

8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. IBM Watson Health (IBM Corporation)

10.2. Google Health (Alphabet Inc.)

10.3. Tempus Labs, Inc.

10.4. Nvidia Corporation

10.5. Deep Genomics, Inc.

10.6. Microsoft Corporation

10.7. Owkin, Inc.

10.8. Benevolentai Ltd.

10.9. Recursion Pharmaceuticals, Inc.

10.10. Cloud Pharmaceuticals, Inc.   

IBM Watson Health (IBM Corporation)

Google Health (Alphabet Inc.)

Tempus Labs, Inc.

Nvidia Corporation

Deep Genomics, Inc.

Microsoft Corporation

Owkin, Inc.

Benevolentai Ltd.

Recursion Pharmaceuticals, Inc.

Cloud Pharmaceuticals, Inc.